Zoran's Story

How one man's diagnosis of ALS drove him to do more with life

Preapproval vs unapproved or elsewhere approved medicines

What’s the difference between a ‘pre-approval’ medicine and an ‘unapproved’ or ‘elsewhere approved’ medicine’?


Price decreases for 38 medicines

New microneedle product could help people with ALS, MS and diabetes

Remember the hypospray from Star Trek? Maybe it's close to reality

What are the latest breakthroughs in multiple sclerosis (MS)?

The potential of neuroprotective agents for a whole new form of treatment

New medicines coming soon!

A list of medicines TheSocialMedwork will soon be making available

Seeing orange: a quick recap of 2017

A groundbreaking year helping patients access the latest approved medicines

Anatoly's Story

This is Anatoly's own story of 'helping a hero'

Promising Developments in Treatment of Multiple Myeloma!

Darzalex (daratumumab) combination under review as first-line option

Spinraza, the new medicine for spinal muscular atrophy

Is there substance to the claims that it's a groundbreaking treatment?

Staff spotlight: Lieschen

Why can it take us three to four weeks to deliver a medicine, and what can customers do to speed things up?

The Parcel of Success

Why every little package is a big deal.

A new medicine for Alzheimer's disease?

Introducing a breakthrough known as 'CT1812'

TheSocialMedwork makes an impact in Silicon Valley

Our review of the SOCAP social impact event in San Francisco

Fast Forward: to helping even more people

An insight into the team, and how we constantly review our progress at TheSocialMedwork

Telling your child you have cancer

Suggestions from cancer survivors and their children

How effective is Radicava/Radicut (edaravone) for ALS?

An easy-to-understand infographic displaying the results from the clinical trial

Dealing with a Diagnosis

Online counsellor Nicole Hind shares how to help our brains and bodies deal with a diagnosis

30 minutes with Esther Dyson

A chat with our very first angel investor about patients, doctors and injecting innovation into the healthcare sector

Defining ocrelizumab's role within the MS treatment landscape

Gaining a deeper understanding of Ocrevus (ocrelizumab) for the treatment of MS through clinical trials

Trailblazing Amsterdam’s Canals

Amsterdam leads European cities as top tech destination and why it’s only natural that it is home to TheSocialMedwork.

Advances in Multiple Sclerosis (MS) Infographic

Missed our blog on the latest MS news and treatments? Here's a quick summary in our latest infographic.

Edaravone availability in the US - one month to go

As we await the arrival of edaravone to US pharmacies, patients can access edaravone now through TheSocialMedwork.

We made an animated video!

Making an animated video for a startup on a limited budget

“Are you an online dating service?”

On designing a logo that better represents your brand.

PrEP for HIV Prevention

With recent drops in new HIV diagnoses being linked to buying PrEP through online buyers clubs, the addition of PrEP to the WHO's essential medicine list, and the recent approval of generic PrEP in the US - here’s what you need to know.

First books, now medicines

Online shopping giants Amazon turn their eye to the online pharmacy market.

ALS awareness month

What did we get up to, and what's next?

5 things you need to know about multiple sclerosis (MS)

Get the latest news on MS research, the FDA approval of Ocrevus (ocrelizumab) for both relapsing and progressive forms of MS, insights and resources.

Another high price tag for Duchenne muscular dystrophy treatment

PTC Therapeutics announce the launch of Emflaza for the treatment of Duchenne muscular dystrophy (DMD) within the coming weeks, with an expected net price of $​​35,000.

Accessing edaravone in your country - the new FDA approved drug for ALS

What are the results from the clinical studies that led to the approval of edaravone, and how can patients access it in their country?

Science saves lives!

Top 5 medical breakthroughs from the past, present and future

The pricing controversy surrounding Duchenne muscular dystrophy (DMD) treatment

The latest events surrounding the pricing of a Duchenne muscular dystrophy (DMD) treatment.

A patient’s right to try

Mirjam Bink’s story about her father and his attempt to access a new treatment for multiple system atrophy.

A look back, a step forward

TheSocialMedwork organised the perfect spring day to reflect and grow our 2017 startup strategy.

Marriages, businesses, and lots of bubbles!

How our community celebrated remission!

Nivolumab Dominates the News

Promising Results from Multiple Studies

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.